January 5, 2018 / 11:09 AM / a year ago

BRIEF-Ohr Pharmaceutical Announces Efficacy Results From The Mako Study In Wet-Amd

Jan 5 (Reuters) - Ohr Pharmaceutical Inc:

* OHR PHARMACEUTICAL ANNOUNCES EFFICACY RESULTS FROM THE MAKO STUDY IN WET-AMD

* OHR PHARMACEUTICAL INC - ‍TOPLINE DATA FROM MAKO STUDY DID NOT MEET ITS PRIMARY EFFICACY ENDPOINT​

* OHR PHARMACEUTICAL INC - “WE ARE VERY DISAPPOINTED WITH OUTCOME OF MAKO STUDY”

* OHR PHARMACEUTICAL INC - ‍INTEND TO EVALUATE STRATEGIC ALTERNATIVES TO “MAXIMIZE SHAREHOLDER VALUE”​

* OHR PHARMA - SUBJECTS RECEIVING SQUALAMINE COMBINATION THERAPY ACHIEVED MEAN GAIN OF 8.33 LETTERS FROM BASELINE VERSUS 10.58 FROM LUCENTIS MONOTHERAPY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below